TY - JOUR
T1 - Mesothelin-targeted agents in clinical trials and in preclinical development
AU - Kelly, Ronan J.
AU - Sharon, Elad
AU - Pastan, Ira
AU - Hassan, Raffit
PY - 2012/3
Y1 - 2012/3
N2 - Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development.
AB - Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development.
UR - http://www.scopus.com/inward/record.url?scp=84859379903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859379903&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-11-0454
DO - 10.1158/1535-7163.MCT-11-0454
M3 - Review article
C2 - 22351743
AN - SCOPUS:84859379903
SN - 1535-7163
VL - 11
SP - 517
EP - 525
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 3
ER -